Our Pricing

Wegovy Dosing Chart & Real UK Weight Loss Results

Published on: June 03, 2026

Understanding the wegovy dosing chart uk schedule is essential for achieving optimal weight loss outcomes. At Cured Pharmacy, our UK-registered clinical team guides patients through the full titration protocol, from the initial 0.25mg dose through to the maintenance 2.4mg dose, with transparent pricing from £79.00 and discreet delivery across the UK.

Complete Wegovy Dosing Chart UK: The 5-Month Titration Schedule

Wegovy follows a carefully designed dose escalation protocol licensed by the MHRA to minimise gastrointestinal side effects whilst maximising weight loss efficacy [1]. The titration schedule spans 17 weeks before reaching the full maintenance dose of 2.4mg semaglutide once weekly.

The standard Wegovy dosing chart UK prescribers follow begins with 0.25mg weekly for 4 weeks, then increases to 0.5mg for 4 weeks, 1.0mg for 4 weeks, 1.7mg for 4 weeks, and finally 2.4mg as the maintenance dose [1]. Each pen is colour-coded to prevent dosing errors, and patients inject subcutaneously in the abdomen, thigh, or upper arm on the same day each week.

Clinical data from the STEP trials demonstrate that this gradual titration significantly reduces the incidence of nausea and vomiting compared to rapid dose escalation [2]. Approximately 74% of patients in UK clinical practice successfully complete the full titration to 2.4mg when supported by appropriate prescriber guidance.

What Happens If You Miss a Dose?

If you miss your scheduled Wegovy injection and fewer than 5 days have passed, take the missed dose as soon as you remember. If more than 5 days have elapsed, skip the missed dose entirely and resume your normal schedule with the next planned injection [1]. Never double up doses to compensate for a missed injection, as this significantly increases the risk of severe nausea and gastrointestinal distress.

Real UK Weight Loss Results: STEP Trial Data and Patient Outcomes

The landmark STEP 1 trial, which informed Wegovy's UK licensing, demonstrated an average weight loss of 14.9% of initial body weight over 68 weeks in patients receiving the full 2.4mg maintenance dose [2]. This translates to approximately 15.3kg for a patient starting at 105kg baseline weight.

More impressively, 50.5% of participants achieved at least 15% body weight reduction, and 32% lost 20% or more of their starting weight — outcomes previously only achievable through bariatric surgery [2]. These results represent the most significant pharmaceutical weight loss outcomes recorded in clinical trials to date.

In real-world UK clinical practice, results align closely with trial data when patients adhere to the full dosing schedule and maintain lifestyle modifications. Our clinical team at Cured Pharmacy observes that patients typically notice appetite suppression within the first 2-4 weeks, with measurable weight loss becoming evident from week 8 onwards as doses increase.

Factors That Influence Individual Results

Weight loss outcomes vary based on starting BMI, adherence to the dosing schedule, dietary modifications, physical activity levels, and metabolic factors. Patients with higher baseline BMI often achieve greater absolute weight loss, whilst those combining Wegovy with structured dietary support and regular exercise typically see enhanced results compared to medication alone.

How Wegovy Works: Semaglutide's Mechanism of Action

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of natural GLP-1 hormones produced in the gut [3]. When administered, semaglutide binds to GLP-1 receptors in the brain's appetite control centres, particularly the hypothalamus, reducing hunger signals and increasing feelings of satiety after smaller meals.

Unlike earlier weight loss medications that worked through stimulant pathways, semaglutide operates through multiple complementary mechanisms: it slows gastric emptying (making you feel fuller for longer), reduces food cravings, improves glucose regulation, and decreases the reward response to high-calorie foods [3]. This multi-pathway approach explains why clinical outcomes significantly exceed older pharmacological interventions.

The 2.4mg dose used in Wegovy is specifically optimised for weight management and differs from the lower semaglutide doses used in diabetes treatment. At this higher concentration, the appetite-suppressing effects become pronounced enough to generate substantial caloric deficit without requiring extreme dietary restriction.

Common Side Effects and How to Manage Them During Dose Escalation

Gastrointestinal side effects are the most frequently reported adverse events during Wegovy treatment, particularly during the initial titration phases [4]. Nausea affects approximately 44% of patients, typically peaking 2-3 days after each dose increase and subsiding within 1-2 weeks as tolerance develops.

Other common side effects include diarrhoea (30% of patients), constipation (24%), vomiting (24%), and abdominal discomfort [4]. These symptoms are generally mild to moderate in severity and diminish significantly once patients reach stable maintenance dosing. The gradual titration schedule exists specifically to allow the gastrointestinal system to adapt.

Practical management strategies include eating smaller, more frequent meals, avoiding high-fat foods that slow digestion further, staying well-hydrated, and taking the injection on an evening before a lighter activity day. If side effects become intolerable, UK prescribers may extend time at a lower dose before escalating, though this may delay optimal weight loss outcomes.

When to Contact Your Prescriber

Seek immediate medical advice if you experience severe persistent abdominal pain (which may indicate pancreatitis), visual changes, signs of thyroid nodules, severe dehydration from vomiting, or allergic reactions including facial swelling. Most patients tolerate Wegovy well, but these rare serious adverse events require prompt clinical assessment.

Wegovy Dosing Chart UK vs Other Weight Loss Treatments

Compared to daily injectable options like Saxenda (liraglutide), Wegovy's once-weekly administration significantly improves treatment adherence and patient satisfaction. The longer duration of action means more stable appetite suppression throughout the week, whereas daily injections can create fluctuating symptom control.

Newer dual-agonist treatments targeting both GIP and GLP-1 receptors have emerged, demonstrating even greater average weight loss in head-to-head trials. However, Wegovy remains the most extensively studied GLP-1 medication for weight management, with over 4 years of safety data and the longest track record in UK clinical practice [2][5].

Oral weight loss medications like Orlistat work through entirely different mechanisms (blocking fat absorption) and typically produce more modest results averaging 5-10% body weight reduction. For patients with BMI over 35 or those with weight-related comorbidities, injectable GLP-1 treatments like Wegovy represent the most effective pharmaceutical option currently licensed in the UK.

Starting Wegovy at Cured Pharmacy: Assessment, Prescribing and Delivery

All Wegovy prescriptions at Cured Pharmacy require completion of a clinical assessment by our UK-registered prescribers, in accordance with MHRA and GPhC regulations. The online consultation takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any contraindications to semaglutide therapy.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical protocols to ensure patient safety and appropriate prescribing. Pricing is transparent from £79.00 before you begin your consultation, with no hidden fees or subscription requirements. Once approved, medications are dispensed from our UK-registered pharmacy (GPhC 9012511) in 100% discreet packaging.

Your initial prescription will include the starter doses (0.25mg and 0.5mg pens) with clear written instructions on the titration schedule. Follow-up prescriptions for higher doses are issued after clinical review to ensure you're tolerating treatment appropriately and achieving expected weight loss milestones. Our clinical team remains available throughout your treatment journey for dosing queries and side effect management.

What You'll Need for Your Assessment

Before starting your consultation, have your current weight, height, any existing medical conditions, current medications, and previous weight loss attempts documented. This information helps our prescribers determine if Wegovy is clinically appropriate and safe for you, and ensures the most effective treatment plan from the outset.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Müller, T. D., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010 [accessed 13 August 2026]
4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence, lifestyle modifications, and baseline health status.